Advertisment

Higher Hospitalization Rates in Children: Spotlight on RSV, Omicron, and Influenza

author-image
Ethan Sulliva
New Update
NULL

Higher Hospitalization Rates in Children: Spotlight on RSV, Omicron, and Influenza

Advertisment

RSV Leads the Pack in Pediatric Hospitalization Rates

Advertisment

A recent retrospective study has shed new light on hospitalization rates for respiratory syncytial virus (RSV), the omicron strain of SARS-CoV-2, and influenza A/B in children. The study, conducted at Swedish emergency departments, revealed that RSV had the highest hospitalization rate at a staggering 81.7%. Following behind were omicron and influenza, with hospitalization rates of 31.5% and 27.7% respectively.

ICU Admission and Mortality Rates Remain Low

Despite the high hospitalization rates, the study found that Intensive Care Unit (ICU) admission rates were low for all three illnesses. However, RSV had the highest ICU admission rate of the three. Mortality within 30 days after admission was also low, reinforcing that while these illnesses are indeed serious, they are generally well-managed in a hospital setting.

Advertisment

Newborns and Infants at Greater Risk of Hospitalization from RSV

The study further illustrated that the odds of newborns and infants up to one year of age with RSV being hospitalized were about 11 times greater than those diagnosed with omicron. This significant difference underscores the increased vulnerability of this age group to RSV. Common conditions among the hospitalized children included asthma, congenital abnormalities, and perinatal conditions.

FDA-approved Interventions for RSV Prevention

Advertisment

In an effort to combat this trend, the FDA has approved the first maternal RSV vaccine designed to protect newborns from serious RSV infection. The FDA has also green-lighted the monoclonal antibody nirsevimab (Beyfortus) as a preventive measure for all newborns and infants in or entering their first RSV season, as well as children up to 2 years old who are at higher risk for severe RSV disease.

RSV Prevention Hindered by Short Supply of Nirsevimab

However, not all news is positive on this front. In October, the CDC issued a health advisory stating that nirsevimab was in short supply and could leave many children at risk. This shortage highlights a critical challenge in the fight against RSV in children, emphasizing the need for a strategic and broad application of available preventative measures.

Advertisment

The Importance of Preventative Measures Against RSV, Influenza, and COVID-19

RSV is a major contributor to illness in young children, and the modalities that we have now to prevent RSV could, if applied wisely and broadly, significantly reduce hospitalizations and RSV morbidity. In addition to RSV, we cannot ignore the ongoing threat of influenza and COVID-19. With sharp increases in flu levels, COVID-19 cases, and RSV cases, the CDC has warned of a respiratory triple threat. Health experts agree on the importance of making a health plan ahead of time and working to minimize the spread of respiratory illnesses, particularly during holiday gatherings.

Limitations of the Study

Advertisment

While this study provides invaluable insights into the comparative risks of RSV, omicron, and influenza hospitalization in children, it's important to note its limitations. Being a retrospective study, it's subject to potential underreporting of provided respiratory support. Additionally, as it was conducted at Swedish emergency departments, the findings may not be universally applicable.

Conclusion

This study underscores the importance of proactive measures against RSV, influenza, and COVID-19 in the pediatric population. With the FDA's approval of new preventative measures against RSV and the ongoing vaccination efforts against influenza and COVID-19, we are better equipped than ever to protect our children. However, it's imperative that these interventions are applied widely and strategically to effectively reduce hospitalization rates and improve the health outcomes of our youngest population.

Advertisment
Chat with Dr. Medriva !